Skip to main
OMDA

OMDA Stock Forecast & Price Target

OMDA Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 55%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Omada Health Inc. has demonstrated robust financial growth, achieving a total revenue increase of 49.5% year-over-year, driven by a surge in platform membership, which reached 831,000 by the end of Q3 2025—substantially exceeding initial estimates. The company has successfully expanded its GLP-1 program, adding approximately 100,000 members in 2025 and achieving over 50% revenue growth linked to this initiative, highlighting strong demand for its integrated health solutions. Furthermore, predictions of significant growth in the obesity drug market, projected to soar to $60 billion by 2029, align well with Omada's strategic focus on chronic condition management, enhancing its long-term growth prospects.

Bears say

Omada Health Inc has exhibited concerning trends in its financial metrics, particularly with a decrease in adjusted R&D as a percentage of services revenue from 28% in 2023 to 16% in 2025, indicating potential underinvestment in innovation relative to revenue growth. Additionally, the company's current trading multiples of 28x and 21x EBITDA estimates for 2027 and 2028, paired with a projected CAGR of only 54% from 2026 to 2028, suggest investor skepticism about its long-term growth trajectory compared to historical peaks and market expectations. Furthermore, the potential shift of health plans towards internalized care management programs could further constrict Omada's growth prospects, compounded by the introduction of lower-cost oral therapies that may challenge the ongoing demand for its GLP-1 initiatives.

OMDA has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 55% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omada Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omada Health Inc (OMDA) Forecast

Analysts have given OMDA a Buy based on their latest research and market trends.

According to 11 analysts, OMDA has a Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omada Health Inc (OMDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.